The safety profile of low-dose cladribine in refractory rheumatoid arthritis: A pilot trial

Scandinavian Journal of Rheumatology

Volumn 26, Issue 5, 1997, Pages 376-379

  Schirmer, M ^a   Mur, E ^a   Pfeiffer, K P ^a   Thaler, J ^a   Konwalinka, G ^a,b  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Cladribine; Lymphocyte subsets; Nucleoside analog; Rheumatoid arthritis therapy; Side effects

Indexed keywords

ANTIRHEUMATIC AGENT; CLADRIBINE; LITAC; METHOTREXATE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; B LYMPHOCYTE; CLINICAL TRIAL; DRUG SAFETY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; IMMUNOFLUORESCENCE; LEUKOCYTE COUNT; LYMPHOCYTE SUBPOPULATION; LYMPHOCYTOPENIA; MALE; NATURAL KILLER CELL; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SUBCUTANEOUS DRUG ADMINISTRATION; T LYMPHOCYTE;

EID: 0030780827     PISSN: 03009742     EISSN: None     Source Type: Journal    
DOI: 10.3109/03009749709065702     Document Type: Article

References (14)

1. Beutler E. New chemotherapeutic agent: 2-Chlorodeoxy-adenosine. Semin Hematol 1994; 31: 40-5.
2. Carson DA, Wasson DB, Taetle R, Yu A. Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes. Blood 1983; 62: 737-43.
3. + lymphocyte counts in patients with hairy cell leukemia. Blood 1994; 83: 2906-11.
4. Juliusson G, Lenkei R, Liliemark J. Flow cytometry and bone marrow cells from patients with hairy cell leukemia: Phenotype of hairy cells and lymphocyte subsets after treatment with 2-chlorodeoxyadenosine. Blood 1994; 83: 3672-81.
5. Lauria F, Rondelli D, Raspadori D, Benfenati D, Tura S. Rapid restoration of natural killer activity following treatment with 2-chlorodeoxyadenosine in 22 patients with hairy-cell leukemia. Eur J Haematol 1994; 52: 16-20.
6. Betticher DC, Fey MF, von Rohr A, Tobler A, Jenzer H, Gratwohl A, et al. High incidence of infections after 2-chlorodeoxyadenosine (2-CdA) therapy in patients with malignant lymphomas and chronic and acute leukaemias. Ann Oncol 1994; 5: 57-64.
7. Schirmer M, Hilbe W, Geisen F, Thaler J, Konwalinka G. T-cells and natural killer cells after treatment of hairy-cell leukaemia with 2-chlorodeoxyadenosine (2-CdA). Acta Haematol 1997; 97: 180-3.
8. Cheson BD, Vena DA, Foss FM, Sorensen JM. Neurotoxicity of purine analogs: A review. J Clin Oncol 1994; 12: 2216-22.
9. Oberhuber G, Schmid T, Thaler W, Kaltenbacher A, Schirmer M, Liliemark J, et al. 2-Chlorodeoxyadenosine in combination with cyclosporine prevents rejection after allogeneic small bowel transplantation. Transplantation 1994; 58: 743-5.
10. Sipe JC, Romine JS, Koziol JA, McMillian R, Zyroff J, Beutler E. Cladribine in treatment of chronic progressive multiple sclerosis. Lancet 1994; 344: 9-13.
11. Eibschutz B, Baird SM, Weisman MH, Amox DG, Spellman M, Piacquadio D, et al. Oral 2-chlorodeoxyadenosine in psoriatic arthritis: A preliminary report. Arthritis Rheum 1995; 38: 1604-9.
12. Merkel PA, Letourneau EN, Polisson RP. Investigational agents for rheumatoid arthritis. Rheum Dis Clin North Am 1995; 21: 779-96.
13. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 33: 315-24.
14. Steinbrocker O, Traeger CH, Batterman RC. Therapeutic criteria in rheumatoid arthritis. JAMA 1949; 140: 659-62.